Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?

참고문헌 (9)

1. Hyeon Ah Lee, "Characteristics of Pediatric Inflammatory Bowel Disease in Korea: Comparison with EUROKIDS Data", Gut and Liver, 9(6), pp.756~760 (2015), 거트앤리버 발행위원회
2. 김미진, "Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn’s Disease with Infliximab Therapy", Gut and Liver, 9(3), pp.370~380 (2015), 거트앤리버 발행위원회
3. Ben-Horin S, "Tailoring anti-TNF therapy in IBD:drug levels and disease activity", Nat Rev Gastroenterol Hepatol, 11, pp.243~255 (2014)
4. Billioud V, "Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review", Am J Gastroenterol, 106, pp.674~684 (2011)
5. Ben-Horin S, "Optimizing anti-TNF treatments in inflammatory bowel disease", Autoimmun Rev, 13, pp.24~30 (2014)
6. 이강문, "Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID)", Intestinal research, 13(3), pp.193~207 (2015), 대한장연구학회
7. Felice C, "Therapeutic drug monitoring of anti-TNF-alpha agents in inflammatory bowel diseases", Expert Opin Biol Ther, 15, pp.1107~1117 (2015)
8. Khanna R, "Review article: a clinician’s guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease", Aliment Pharmacol Ther, 38, pp.447~459 (2013)
9. 최소윤, "Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease", Gut and Liver, 11(1), pp.55~61 (2017), 거트앤리버 발행위원회